MacroGenics develops cancer medicines made from antibodies and runs a manufacturing facility in Maryland. MGNX reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 17 | B. Riley Securities | Target raised | Buy | |
| Apr 10 | B. Riley Securities | Upgrade | Buy |
Seasonality
How MGNX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
Whale Options Flow
90DNo whale options trades in MGNX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MGNX is in one of them and how their past MGNX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MGNX in an article yet. Here's the latest on the wider market.
About Macrogenics
MacroGenics is a biopharmaceutical company based in Rockville, Maryland that develops medicines made from antibodies to treat cancer. Its drug candidates use antibody technologies such as antibody drug conjugates and antibodies that act on more than one target, and several have been partnered with larger drug companies. The company also runs a manufacturing facility in Maryland that supports its own programs and provides contract development and manufacturing services to collaborators and other third parties.
- Headquarters
- Rockville, MD